-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

570 Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma

Program: Oral and Poster Abstracts
Type: Oral
Session: 624. Hodgkin Lymphomas: Clinical and Epidemiological: Optimization of Therapy
Hematology Disease Topics & Pathways:
Research, Hodgkin lymphoma, Lymphomas, Elderly, Clinical Research, Health outcomes research, Diseases, Real-world evidence, Lymphoid Malignancies, Study Population, Human
Sunday, December 8, 2024: 1:15 PM

Sanjal H. Desai, MBBS1,2, Michael A Spinner, MD3, Alice Sykorova4*, Veronika Bachanova, MD, PhD5, Andrew M Evens, DO MBA MSc6, Gaurav Goyal, MD7, Brad S. Kahl, MD8, Kathleen Dorritie, MD9, Jacques Azzi10, Vaishalee P Kenkre, MD11, Cheryl Chang, BA12*, Jozef Michalka, MD13*, Stephen M. Ansell, MD, PhD14, Brendon Fusco, MD15, Nuttavut Sumransub, MD5, Haris Hatic, DO16, Raya Saba, MD, MS17, Uroosa Ibrahim, MD18, Elyse I Harris, MD11*, Harsh R. Shah, DO19, Nina D. Wagner-Johnston, MD20, Sally Arai, MD21, Grzegorz S. Nowakowski, MD2, Heidi Mocikova, MD22*, Deepa Jagadeesh, MD23, Kristie A. Blum, MD24, Catherine S. Diefenbach, MD25, Siddharth Iyengar, MD26*, K. C. Rappazzo, MD27*, Firas Baidoun, MD28, Yun Choi, MD29*, Vit Prochazka, MD, PhD30, Ranjana H. Advani, MD31 and Ivana N. Micallef2*

1Masonic Cancer Center, University of Minnesota, Minneapolis, MN
2Mayo Clinic, Rochester, MN
3Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA
44th Department of Internal Medicine– Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, CZE
5Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN
6Rutgers Cancer Institute, New Brunswick, NJ
7University of Birmingham Alabama, Birmingham, AL
8Department of Medicine, Washington University School of Medicine, St. Louis, MO
9UPMC Hillman Cancer Center, Pittsburgh, PA
10Division of Hematology & Medical Oncology, Cellular Therapy and Bone Marrow Transplant, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
11Carbone Cancer Center, University of Wisconsin–Madison, Madison, WI
12Duke University School of Medicine, Durham, NC
13Hematology, Faculty of Medicine Masaryk University and University Hospital Brno, Brno, Czech Republic
14Division of Hematology, Mayo Clinic, Rochester, MN
15Department of Hematology & Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
16Suburban Hematology-Oncology Associates-Lawrenceville, Lawrenceville, GA
17Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, Kansas City, MO
18Division of Hematology & Medical Oncology, Cellular Therapy and Bone Marrow Transplant, Tisch Cancer Institute/ Icahn School of Medicine at Mount Sinai, New York, NY
19Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
20Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD
21Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
22Department of Internal Medicine – Hematology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, AE
23Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
24Winship Cancer Institute of Emory University, Atlanta, GA
25Perlmutter Cancer Center at NYU Langone Health, New York, NY
26Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
27Division of Hematology, Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
28Cleveland Clinic Taussig Cancer Center, Cleveland, OH
29Perlmutter Cancer Center At NYU Langone Health, NYU Grossman School of Medicine, New York, NY
30Head of the Lymphoma Research Group, Department of Hemato-Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Olomouc, Czech Republic
31Department of Medicine, Division of Oncology and Hematology, Stanford University, Stanford, CA

Introduction: Adults older than 60 years constitute 20-25% of newly diagnosed classic Hodgkin lymphoma (cHL) and have inferior outcomes compared to younger patients (pts). Salvage therapy followed by an autologous stem cell transplant (ASCT) is a potentially curative option for pts with relapsed/refractory (R/R cHL). There is limited data regarding outcomes of older adults with R/R cHL who undergo ASCT in the current era where novel agents are employed in the R/R setting, in comparison with younger patients.

Methods: This multicenter, international, retrospective study of 18 participating institutions included adults with R/R cHL who underwent ASCT from January 1, 2010 through December 31 2020. Retrospective chart review was performed to collect data on patient and disease characteristics at relapse, including lines and type of salvage therapy, pre-ASCT response by PET, and use of brentuximab vedotin (BV) as consolidation post-ASCT. Study objectives were to assess progression-free survival (PFS), overall survival (OS), and the probability of non-relapse mortality (NRM) with relapse as a competing event. NRM was defined as death without preceding relapse.

Results: Of the total 1172 adults with R/R cHL enrolled in the parent cohort, 96 (8.1%) were age 60 years or older at the time of ASCT. In this older cohort, the median age was 66 years (range: 60-72). 54 (56%) were age 60-64, 31 (32%) were of age 65-69 and 11 (11%) were of age 70-72. 59 (61%) were male, 63 (66%) had advanced stage disease, 17 (18%) had bulky disease, 37 (39%) had B symptoms and 38 (40%) had extranodal disease. All patients (pts) received ABVD or ABVD-like frontline therapy. The median time to relapse was 6 months (range: 0-174). 48 pts (50%) relapsed within a year after completion of frontline treatment and 25 (26%) had primary refractory disease. Salvage therapy prior to ASCT included platinum-based chemotherapy (65%), BV-based regimen (34%), and PD-1 inhibitor-based regimens (3%). 16 pts (16%) underwent ASCT after >1 line of salvage therapy and 75 (78%) underwent ASCT after achieving a complete metabolic response (CMR). 14 pts (14.6%) received BV consolidation.

Median follow-up for entire population was 53.4 months (range: 0.3-199.0). In older adults, the 5-year PFS was 54.2% (CI95: 43.4-67.6) not statistically different compared to pts <60 years (67.7% (CI95: 64.3-71.3), p=0.2). However, 5-year OS was inferior in older adults: 71.9% (CI95: 43.4-67.6) vs. 82.6% (CI95: 43.4-67.6) in pts <60 years (p <0.0001)). In pts ≥60, 26 (27%) died including 12 (12.5%) without preceding relapse. Older adults had 3-month, 1-year and 5-year probability of NRM of 5.2% (CI95: 2.2-12.2), 7.5% (CI95: 3.6-15.3), and 10.9% (CI95: 5.8-20.8), respectively. NRM was significantly higher in older adults compared to pts <60 who had 3-month, 1-year and 5-year probability of NRM of 0.3% (CI95: 0.1-1.0), 0.9% (CI95: 0.5-1.7), and 2.5% (CI95: 1.6-3.9), respectively (p<0.0001). Older adults had 3-month, 1-year and 5-year probability of relapse of 1% (CI95: 0.2-7.3), 7.5% (CI95: 3.6-15.3), and 28.6% (CI95: 19.1-42.1), respectively, which did not differ significantly from younger pts (p=0.3) who had 3-month, 1-year and 5-year probability of relapse of 0.6% (CI95: 0.3-1.3), 5.1% (CI95: 3.8-6.6), and 29.9% (CI95: 26.6-33.5), respectively.

Conclusions: Although older adults with cHL are more likely to relapse after frontline treatment, only a minority of pts (<10%) in this large multicenter cohort underwent ASCT at age ≥60. In select older adults who underwent ASCT, the risk of relapse was similar to younger pts, but NRM was significantly higher, especially in the early post-ASCT period. Detailed assessment of comorbidity scores, toxicities of salvage therapies, and prognostic factors will be presented at the conference.

Disclosures: Desai: Onclive: Honoraria; CurioScience: Honoraria; Merck: Research Funding; Beigene: Research Funding. Spinner: Gilead/Kite: Consultancy; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees. Bachanova: Citius: Research Funding; Incyte: Research Funding. Evens: Incyte: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Genentech: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pharmacyclics: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria. Kahl: AstraZeneca: Consultancy, Research Funding; Lilly: Consultancy, Honoraria; BeiGene: Consultancy, Research Funding; Roche: Consultancy, Research Funding; ADCT: Consultancy; Genentech: Consultancy; AbbVie: Consultancy; Bristol Myers Squibb: Consultancy, Honoraria. Dorritie: BMS: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; Kite-Gilead: Research Funding; Hoffman La-Roche: Research Funding; Genmab: Research Funding. Kenkre: Ipsen: Research Funding. Ansell: Affimed: Membership on an entity's Board of Directors or advisory committees, Research Funding; ADC Therapeutics: Research Funding; AstraZeneca: Research Funding; Bristol Myers Squibb: Research Funding; Pfizer: Research Funding; Regeneron Pharmaceuticals, Inc.: Research Funding; SeaGen: Research Funding; Takeda: Research Funding. Shah: Incyte, Epizyme, Seattle Genetics, Loxo Oncology, Acerta: Research Funding; AbbVie, Seattle Genetics: Consultancy. Wagner-Johnston: AstraZeneca: Research Funding; Beigene: Consultancy; Genentech: Research Funding; Merck: Research Funding. Nowakowski: AbbVie Inc.: Consultancy; MorphoSys AG: Consultancy, Research Funding; TG Therapeutics Inc: Consultancy; ADC Therapeutics: Consultancy; Bantam Pharmaceutical, LLC: Consultancy; Segen: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; F. Hoffmann-La Roche Limited: Consultancy; Constellation Pharmaceuticals: Consultancy; Kymera Therapeutics: Consultancy; Karyopharm Therapeutics: Consultancy; MEI Pharma: Consultancy; Fate Therapeutics: Consultancy; Genentech: Consultancy; Blueprint Medicines Corporation: Consultancy; Celgene Corporation: Consultancy, Research Funding; Debiopharm: Consultancy; Daiichi Sankyo: Consultancy; Zai Laboratory: Consultancy; Ryvu Therapeutics: Consultancy; Selvita Inc: Consultancy; Curis: Consultancy, Research Funding; Incyte Corporation: Consultancy. Mocikova: Eli Lilly: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen Cilag: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees. Jagadeesh: Affimed, Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees; AstraZeneca, ATARA Biotherapeutics, Debio Pharma, LOXO Pharmaceuticals, MEI Pharma, Regeneron Pharmaceuticals, Inc., Seagen, Trillium Pharmaceuticals: Research Funding. Diefenbach: FATE Therapeutics: Consultancy, Research Funding; Morphosys: Consultancy, Research Funding; Millenium: Research Funding; Merck: Consultancy, Research Funding; Gilead: Current equity holder in publicly-traded company, Research Funding; Genmab: Consultancy, Research Funding; Genentech/Roche: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Research Funding; MEI Pharma: Consultancy, Research Funding; I MAB: Consultancy, Current equity holder in private company; NYU Grossman School of Medicine/Perlmutter Cancer Center at NYU Langone Health: Current Employment; OverT Therapeutics: Current equity holder in private company; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Seattle Genetics: Consultancy, Research Funding. Prochazka: Abbvie: Consultancy; Eli Lilly: Consultancy; Novartis: Consultancy; Swixx: Consultancy, Speakers Bureau. Advani: Seattle Genetics: Research Funding; Cyteir: Research Funding; Regeneron: Research Funding; Autolus: Honoraria, Other: DSMB/Advisory Boards; Gilead: Research Funding; Merck: Other: Steering committee, DSMB/Advisory Boards, Research Funding; ADCT: Honoraria, Other: DSMB/Advisory Boards; BeiGene: Honoraria, Other: DSMB/Advisory Boards, Research Funding; Roche/Genentech: Honoraria, Other: Steering committee, DSMB/Advisory Boards, Research Funding.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH